← Human Trials & Peer-Reviewed Studies
Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia
Plain-language guide to PMID 29099978 (2018): double-blind randomized controlled trial study of GIP (Gastric Inhibitory Polypeptide).
Key Facts
- PMID
- 29099978
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Christensen MB et al. (7 authors)
- DOI
- 10.1210/jc.2017-01949
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at GIP (Gastric Inhibitory Polypeptide).
To study if GIP affects bone homeostasis biomarkers independently of insulin release and glycemic level.
Why It Was Studied
The gut hormone glucose-dependent insulinotropic polypeptide (GIP) causes postprandial insulin release and inhibits bone resorption assessed by carboxy-terminal collagen crosslinks (CTX).
Who Took Part
The age groups tagged for this paper are adults, men only.
Ten male C-peptide-negative patients with type 1 diabetes.
How the Study Was Run
The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.
Because people in this GIP (Gastric Inhibitory Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Blinding on both sides kept the participants and researchers unaware of who received GIP (Gastric Inhibitory Polypeptide).
A placebo (an inactive look-alike) gave the GIP (Gastric Inhibitory Polypeptide) group a baseline to be compared against.
Each person switched between GIP (Gastric Inhibitory Polypeptide) and the comparison at some point, usually with a gap in between.
Randomized, double-blinded, crossover study with 5 study days.
What Was Measured
The gut hormone glucose-dependent insulinotropic polypeptide (GIP) causes postprandial insulin release and inhibits bone resorption assessed by carboxy-terminal collagen crosslinks (CTX).
Topics PubMed links to this paper include Biomarkers, Blood Glucose, Bone Resorption, C-Peptide, Diabetes Mellitus, Type 1, Gastric Inhibitory Polypeptide and Gastrointestinal Agents.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of GIP (Gastric Inhibitory Polypeptide).
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2018 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compound
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.